Rybelsus® vs. Wegovy® for Weight Loss
Administration & Purpose
Rybelsus is an oral tablet taken daily, primarily prescribed for managing type 2 diabetes. It helps improve blood sugar control by mimicking the hormone GLP-1, which stimulates insulin release and slows gastric emptying, thus reducing appetite.
Wegovy is an injectable medication taken once weekly and is approved for chronic weight management in adults and adolescents with obesity or overweight conditions. Like Rybelsus, it also mimics GLP-1 to reduce appetite and increase insulin secretion.
Rybelsus Effectiveness
For weight loss, Wegovy has shown to be more effective compared to Rybelsus. Clinical trials indicate that Wegovy can support an average weight loss of around 11% after 26 weeks and up to 16% after one year. In comparison, Rybelsus supports an average weight loss of about 4.5% after 26 weeks.
Higher dosage of Rybelsus are being investigated, and some studies suggest that these might offer weight loss similar to Wegovy, but currently, Rybelsus is only approved up to 14 mg for diabetes treatment.
More About Rybelsus
Patient Reviews: Rybelsus has an average rating of 6.1 out of 10 based on 227 reviews, with 47% of reviewers reporting a positive effect and 29% reporting a negative effect. Wegovy has a higher average rating of 7.3 out of 10 from 361 reviews, with 63% of users reporting a positive effect and 20% reporting a negative effect.
Cost: The cost of Rybelsus is approximately $1,029.35 for a month’s supply (30 tablets of 3 mg each). Wegovy costs around $1,430.01 for a month’s supply (2 mL of 0.25 mg/0.5 mL).
Conclusion: Wegovy is generally more effective for weight loss, while Rybelsus is primarily targeted at managing type 2 diabetes. Both have similar side effects and are costly without insurance. The choice between the two depends largely on the specific health needs and treatment goals of the patient.
Semaglutide
- 1ml/2.5mg
Semaglutide
- 3ml/12.75mg
Tirzepatide
- 50mg/5ml
